On the stock market since 2005, it operates in the world of health and science. It has 114 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 9 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $6.3M against $30.7M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.
On our five-subject report card, SSKN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SSKN is a small company that closed last year at a loss. The road back to profit runs through spending discipline.